SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : genelabs(gnlb) -- Ignore unavailable to you. Want to Upgrade?

To: JMarcus who wrote (119)3/19/1998 4:54:00 PM
From: Biotech  Respond to of 233
 
The press release on 3/3/98 concerning GNLB's agreements with Tripos, MDS Panlabs and SRI Intl is a very important announcement. First-off, Tripos is a well respected firm and is a technology leader. Secondly, by capturing these combinatorial chemistry libraries, GNLB's has additional libraries of molecules to analyze with Merlin. Lastly, as the press release reads, SRI Intl will produce molecules made to GNLB specifications. This says to me that GNLB is closer to beginning live testing of its molecules. It is getting interesting!



To: JMarcus who wrote (119)4/13/1998 8:28:00 AM
From: Biotech  Read Replies (2) | Respond to of 233
 
Interesting article written by a respected biotech analyst on GNLB and ISIP concerning the DARPA relationship. You can find the article at www.talks.com under the medicine man. Bottom line, the "medicine man" believes GNLB is very undervalued and the DARPA relationship should give investors confidence that GNLB's has leading edge technology.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News